Significant stock movers of September: Viking soars, Longeveron slides
Viking Therapeutics (VKTX) rose 24% in September after positive Phase 1 data for VK2735, a weight-loss drug, but ended the month down 3.18% due to a $575M financing. Longeveron (LGVN) fell 64% after its stem cell therapy failed a Phase 2b trial, triggering a strategic review. The broader biotech sector declined 3.5% in September.
How this was made
The 30-second read
Why it matters
Both companies experienced material news that directly affected their share prices, offering clear trading signals.
Market read
Provides actionable insight for biotech traders on immediate price moves and longer‑term pipeline considerations.
What to watch
Longeveron's pipeline beyond laromestrocel may offer future upside if alternative indications succeed.
Background
The article reviews two biotech stocks that moved sharply in September due to distinct clinical and financing events.
Ticker impact
Viking Therapeutics reported Phase 1 data showing 17.7% weight loss and announced a $575 million financing round, driving a 30% stock surge then modest decline.
mixed pressure as market weighs data benefits against dilution
Data is material and fresh; investors will price both the efficacy news and the sizable equity/convertible raise.
Market effects
Highlights divergent trajectories in biotech: positive early‑stage data can boost financing, while late‑stage failures depress peer sentiment.
US biotech sector may see modest net impact as Viking's gain offsets Longeveron's loss.
Limited to investors focused on clinical‑stage biopharma.
Counterpoint
Viking's financing could be seen as over‑capitalization, suggesting a longer‑term downside despite trial data.
Key entities
- companyViking Therapeutics
Biotech with GLP‑1/GIP dual agonist candidate VK2735.
- companyLongeveron
Cell‑therapy developer whose lead asset laromestrocel failed Phase 2b.
